Report Preview

Acute Vulvovaginal Candidiasis Treatment Market

The global acute vulvovaginal candidiasis treatment market size was valued at USD 320 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 3.0% in the forecasted period. The high research and development on drugs and treatments of vulvovaginal candidiasis, are among the prime factors boosting the industry growth. Moreover, close race between the market players to submit the new drug application (NDA) to the governing bodies which will allow them the approval for developing their drugs. This factor is anticipated to propel the growth of global acute vulvovaginal candidiasis market. Conversely, the occurrence of COVID-19 epidemic acts as the hindrance in the acute vulvovaginal candidiasis treatment market in the forecasted period.

Increasing incidence of vaginal fungi infections are boosting acute vulvovaginal candidiasis treatment market growth. For example, as per the Centers for Disease Control and Prevention (CDC), 2018, about 1.4 million outpatient visits happen for vaginal candidiasis each year in the U.S. Furthermore, as per an article issued in Multidisciplinary Digital Publishing Institute (MDPI) in February 2020, Vulvovaginal candidiasis (VVC) is the most prevailing human candida infection and approximately 75% women across the world are affected by it least once in their lifespan. Moreover, as per the same source, nearby 8% women around the world suffer from recurrent vulvovaginal candidiasis (RVVC). As per an NCBI article, VVC is a common infection among women affecting around 138 million women annually worldwide.

According to an NCBI editorial, worldwide, complex VVC infects about 10-20% of women and 9% of women report recurrent VVC cases. Additionally, an increase in the prevalence of the disease is observed owing to growing diabetic patients and escalating antibiotic resistance cases amongst individuals. It is also expected that nearby 15% of such cases need special therapeutic considerations. Thus, the growing prevalence of the disease is boosting industry growth. The growing demand for better healing options is leading to inventions in R&D, new approvals, and introductions of drugs, thereby creating a profitable opportunity for industry growth.

Growing product launches and increasing product approvals are anticipated to boost growth of the global acute vulvovaginal candidiasis treatment market during the forecasted period. For example, in December 2016, Dr. Reddy’s Laboratories broadcasted the introduction of Nystatin and Triamcinolone Acetonide Cream, USP, in the U.S. It is the generic equal of Nystatin and Triamcinolone Acetonide Cream, produced by Taro Pharmaceuticals USA Inc.

Furthermore, key players in the market are implementing various strategies, such as business expansion, to reinforce their market place, which, is anticipated to drive the global acute vulvovaginal candidiasis treatment market growth. For example, in June 2016, Valeant Canada, a subsidiary of Bausch Health Companies Inc. declared that it is increasing its manufacturing and export capability in Canada.

The eruption of COVID-19 has unfavourably affected many nations owing to the lockdown imposed by governments to stop the spread of the virus. The pandemic has also hindered the production, development, and supply of drugs and other healthcare products, and the growth of the global acute vulvovaginal candidiasis treatment market.

As a result, many orthopaedic doctors were organized to monitor patients suffering from coronavirus infection. Moreover, there has been an upsurge in the manufacture of drugs and research and development to manage such patients. The extensive new coronavirus all over the globe has slightly affected the growth of the market. The demand for drugs for vulvovaginal candidiasis was high owing to the increasing prevalence of candidiasis among patients who have suffered from COVID-19. This is as of the increase in healthcare-associated infections and bloodstream contaminations, particularly among those who were admitted to hospitals. Due to all these factors, the market has rapidly improved after the first quarter of 2020 and is further predicted to continue to grow.

Drug Type Insights

In terms of drug type, the global acute vulvovaginal candidiasis treatment market can be bifurcated into clotrimazole, nystatin, ketoconazole, fluconazole, terbinafine, terconazole, and others. The clotrimazole segment is anticipated to lead the global market during the forecasted period owing to high efficacy and usage of clotrimazole drug for the treatment of acute vulvovaginal candidiasis.

Route of Administration Insights

The oral segment dominated the industry in 2021 and accounted for the maximum share of more than 42% of the total revenue. It is predicted to continue its share throughout the forecast period due to the common & suitable route of administration for azoles, good bioavailability, and use for anti-fungal drugs. Oral fluconazole is the most widespread prescription drug acclaimed as treatment and maintenance therapy. It is also active as short-duration therapy in recurrent VVC cases. Lately, the FDA has accepted two oral dosage regimes of VIVJOA (oteseconazole) to decrease incidences of recurrent VVC. The topical segment is projected to grow at a stable CAGR during the study period.

A strong existence of topical products such as over-the-counter and prescription formulations boost the demand in the market. OTCs include Miconazole cream, Clotrimazole cream, and Tioconazole ointment, while Butoconazole cream and Terconazole cream are recommendation formulations. Additionally, topical antifungal recommendations also include econazole and nystatin in the market for more than 30 years. As per the IDSA guidelines, simple VVC should be treated with topical antifungal agents. Moreover, oral azoles are unproductive in treating. Glabrata vulvovaginitis, thereby, is recommended for topical intravaginal boric acid or topical flucytosine cream.

Distribution Channel Insights

On the basis of distribution channels, the industry has been characterized into retail pharmacy, online pharmacy, and hospital pharmacy. The retail pharmacy segment is anticipated to observe the fastest CAGR of more than 4% during the forecasted period. As disease treatment, control and management take short- as well as long-term support of medicines, which increases the segment growth. The market has both prescription and OTC drugs, thereby pharmacists play a significant role by counselling patients and attaining their trust. Retail pharmacies are at comfort for most medicines, especially in the homecare location. All these factors are anticipated to fuel the segment’s growth.

The online pharmacy distribution channel segment is also anticipated to grow at a significant CAGR during the estimated period. The inclination for online purchasing is high owing to the convenience and other profits, such as home delivery. During the pandemic, people experienced the comfort of delivery services and decreased travel time for prescription fill in retail stores. The COVID-19 pandemic enhanced the online segment owing to the government limitations like nationwide lockdowns and stay-at-home guidelines to restraint the spread of the virus.

Region Insights

North America controlled the global industry in 2021 and accounted for the maximum share of more than 37% of the complete revenue. The region is anticipated to expand further at a steady growth rate preserving its leading position through the forecasted period. This supremacy can be accredited to the high disease occurrence, increase in patient awareness, augmented healthcare expenditure, and the existence of major players in the region. Advanced healing options, new approvals, introductions, and proactive government procedures further contribute to regional market growth.

On the other hand, Asia Pacific is projected to witness the fastest growth rate over the forecast years. The high growth rate can be credited to the increasing disease burden of VVC and growing testing rates. Positive changes, such as healthcare assistances by the government, augmented awareness among consumers, and inclination to avail medical treatments are also projected to drive growth in the region. Moreover, rising awareness about this infection amongst the rural women and the initiatives such as ‘Swachhta, Swasthya and Suvidha’ taken by the Indian government for the hygiene of deprived women, are the boosting factors for the growth of global acute vulvovaginal candidiasis market in this region.

Key Companies Insights

The market for acute vulvovaginal candidiasis treatment is moderately competitive. With the rising applications of Acute vulvovaginal candidiasis treatment, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Acute vulvovaginal candidiasis treatment market, ultimately boosting the market growth. Some of the key companies working in the global Acute vulvovaginal candidiasis treatment market include:

• Astellas Pharma Inc.
• Mycovia Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd.
• Pfizer Inc.
• ANI Pharmaceuticals, Inc.
• Lupin Limited
• Hikma Pharmaceuticals Plc.
• Unique Pharmaceuticals
• Glenmark Pharmaceuticals Limited
• PEPTONIC medical AB
• Reddy’s Laboratories
• Aurobindo Pharma Limited
• SCYNEXIS, Inc.
• Other players

Some of the Recent Developments:

• In August 2022, VIVJOA an oral drug successfully received FDA approval. Mycovia Pharmaceuticals’ VIVJOA is an antifungal drug, which selectively prevents fungal CYP5.
• In June 2021, Scynexis, Inc. announced the FDA sanction for their latest drug BREXAFEMME (Ibrexafungerp) designated for VVC treatment.
• In February 2021, Scynexis declared its agreement with the pharmaceutical company, Amplity Health to range their support for the U.S. commercialization of Brexafemme which is a brand name of Ibrexafungerp for vaginal infections.
• In February 2019, Aurobindo Pharma Limited acquired marketable operations and definite supportive structure of Apotex Inc. in five European countries.

Segments

By Drug Class

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

By Route of Administration

• Oral
• Intravenous
• Topical

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt